Previous Article | Next Article 
Journal of Virology, August 1999, p. 6293-6298, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Second-Site Reversion of a Human Immunodeficiency
Virus Type 1 Reverse Transcriptase Mutant That Restores Enzyme
Function and Replication Capacity
Isabel
Olivares,1
Víctor
Sánchez-Merino,1
Miguel A.
Martínez,2
Esteban
Domingo,3
Cecilio
López-Galíndez,1 and
Luis
Menéndez-Arias3,*
Centro Nacional de Biología
Fundamental, Instituto de Salud Carlos III, 28220 Majadahonda
(Madrid),1 Fundación Irsi-Caixa,
Hospital Universitario Germans Trias i Pujol, Badalona
(Barcelona),2 and Centro de
Biología Molecular "Severo Ochoa," Consejo Superior de
Investigaciones Científicas-Universidad Autónoma de
Madrid, Cantoblanco, 28049 Madrid,3 Spain
Received 17 March 1999/Accepted 10 May 1999
 |
ABSTRACT |
Nonconservative substitutions for Tyr-115 in the reverse
transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) lead
to enzymes displaying lower affinity for deoxynucleoside triphosphates
(dNTPs) (A. M. Martín-Hernández, E. Domingo, and L. Menéndez-Arias, EMBO J. 15:4434-4442, 1996). Several mutations at this position (Y115W, Y115L, Y115A, and Y115D) were introduced in an
infectious HIV-1 clone, and the replicative capacity of the mutant
viruses was monitored. Y115W was the only mutant able to replicate in
MT-4 cells, albeit very poorly. Nucleotide sequence analysis of the
progeny virus recovered from supernatants of four independent
transfection experiments showed that the Y115W mutation was maintained.
However, in all cases an additional substitution in the primer grip of
the RT (M230I) emerged when the virus increased its replication
capacity. Using recombinant HIV-1 RT, we demonstrate that M230I
mitigates the polymerase activity defect of the Y115W mutant, by
increasing the dNTP binding affinity of the enzyme. The second-site
suppressor effects observed were mediated by mutations in the 66-kDa
subunit of the RT, as demonstrated with chimeric heterodimers.
Examination of available crystal structures of HIV-1 RT suggests a
possible mechanism for restoration of enzyme activity by the
second-site revertant.
 |
INTRODUCTION |
Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) plays an essential role in the
replication of the single-stranded genomic RNA of the virus. Reverse
transcription involves the synthesis of a double-stranded proviral DNA
which integrates in the host genome, in a process mediated by the
RNA-dependent and DNA-dependent polymerase and the endonuclease (RNase
H) activities of the enzyme (for recent reviews, see references
1, 10, and 31). HIV-1 RT is also
a target for chemotherapeutic intervention in the control of AIDS. The
crystallographic structure of HIV-1 RT has been determined in the
absence of ligands (28), complexed with nonnucleoside RT
inhibitors (15), and complexed with double-stranded DNA
(13). In addition, a crystal structure of a covalently
trapped catalytic complex of HIV-1 RT containing a DNA template-primer
and a deoxynucleoside triphosphate (dNTP) has been recently reported
(11). HIV-1 RT is a heterodimer composed of two subunits of
66 and 51 kDa, with subdomains termed fingers, thumb, palm, and
connection in both subunits and an RNase H domain in the larger subunit
only. The polymerase active site resides within the palm subdomain of
the 66-kDa subunit, which contains the catalytic aspartic acid residues 110, 185, and 186. Other residues in their vicinity, such as Lys-65, Arg-72, Asp-113, Ala-114, Tyr-115, and Gln-151, are involved in the
interaction with the incoming dNTP (11). The role of these amino acids in polymerase function has been investigated by
site-directed mutagenesis (3, 33, 36). Nonconservative
substitutions at several of these positions often lead to the loss of
RT function and virus viability (16).
In previous studies, we used site-directed mutagenesis to produce HIV-1
RT variants with substitutions at Tyr-115. This amino acid was
systematically replaced by Phe, Trp, Val, Ile, Met, Leu, Ala, Ser, Cys,
Asn, His, Gly, Asp, Lys, and Pro. While the substitution of Phe for
Tyr-115 rendered RT fully active, other replacements affected the
polymerase activity of the enzyme, by increasing the
Km values for the incorporation of dNTPs
(17, 18), suggesting an altered dNTP binding function. This
effect was more pronounced in those variant RTs with smaller and less
hydrophobic side chains at position 115. To study the viability of
virus harboring mutations at position 115, we introduced the
substitutions Y115W, Y115L, Y115A, and Y115D in the RT of an infectious
HIV-1 clone by site-directed mutagenesis. In transfection experiments
with one of the variant RTs (Y115W mutant), viable virus was recovered,
but in all cases, the genotypic analysis of the progeny revealed that
it contained an additional substitution at position 230 (Ile instead of
Met). This second-site reversion appears to compensate for the dNTP binding defect shown by the Y115W mutant.
 |
MATERIALS AND METHODS |
Cell lines and molecular clones.
COS-1 cells and MT-4 cells
were maintained as monolayer and suspension cultures, respectively, in
RPMI 1640 medium supplemented with 10% fetal bovine serum and 2 mM
glutamine. Virus used in this study was an infectious molecular clone
of HIV-1 isolate 89ES061 previously described (21, 22). The
5' end of the proviral DNA, including the 5' long terminal repeat
region and the viral genes gag, pol, and
vif, was cloned in the XbaI and EcoRI
sites of plasmid pBSK (Stratagene) to obtain plasmid p61F A. The 3' end
of the proviral DNA, including the env gene and the 3' long terminal repeat, was cloned in pBSK at the EcoRI and
XbaI sites to generate plasmid p61F B. Cotransfection with
plasmids p61F A and p61F B renders virus infectious after in vivo
ligation (21). MT-4 cells were a gift of D. D. Richman
(University of California at San Diego). Mutant HIV clones were
obtained by site-directed mutagenesis. A 4,385-bp
PstI-SalI fragment derived from p61F A, which
contains the entire pol gene, was cloned in the mutagenesis vector pALTER-1 (Promega). In vitro mutagenesis reactions were carried
out by following the manufacturer's instructions, and mutations Y115W,
Y115L, Y115A, and Y115D were introduced with the mutagenic
oligonucleotides previously described (17, 18). The
mutagenized PstI-SalI insert was then excised and
cloned back into p61F A for its use in the transfection experiments.
DNA transfection experiments.
Transfections were performed
as previously reported (21). Briefly, 3 × 106 COS-1 cells were electroporated with 10 µg of
subgenomic clones p61F A and p61F B. Forty-eight hours after
transfection, 4 × 106 MT-4 cells were added to the
culture. Viral replication was monitored by RT activity and p24 antigen
detection in culture supernatants. Virion-associated RT activity was
determined as described by Willey et al. (34), after 10 µl
of transfection supernatant was mixed with 50 µl of an RT reaction
mixture which contained a template-primer of poly(rA) (5 µg/ml) and
oligo(dT)12-18 (1.57 µg/ml) in 50 mM Tris (pH 7.8)-75
mM KCl-2 mM dithiothreitol-5 mM MgCl2-0.05% Nonidet
P-40-0.5 µCi of [32P]dTTP (800 Ci/mmol). In some
assays, cold dTTP was added to the reaction mixture to achieve a final
nucleotide concentration of 10 µM. Production of p24 antigen in
cell-free supernatants was measured with an antigen capture kit (SAIC
Frederick, AIDS Vaccine Program).
Infections.
Supernatants from transfection experiments
collected on days when maximum levels of p24 antigen were detected were
used to infect 5 × 106 fresh MT-4 cells. Viruses were
grown to obtain a stock, which was then titrated in an MT-4 plaque
assay (9, 29). Infections were carried out at a multiplicity
of infection of 0.01 PFU per cell, and viral replication was monitored
by measuring RT activity in culture supernatants and determination of
cell viability by the trypan blue staining method.
RNA isolation, amplification, and nucleotide sequence
analysis.
Culture supernatants were passed through
0.45-µm-pore-size filters and treated with DNase A for 30 min to
eliminate input DNA. Total RNA was obtained from 20 µl of treated
transfection supernatants (2). RNA amplification was done
with the one-tube RT-PCR PCR system (Titan; Boehringer Mannheim) with
primers 47RU (5' GTATTAGTAGGACCTACACCT 3', positions 2055 to
2075) and 59RD (5' ATGATTCCTAATGCATATTGTGAGT 3',
complementary to positions 3622 to 3646). Primers are numbered
according to the sequence of Ratner et al. (27). These
primers amplify a 1,591-bp fragment. After reverse transcription at
50°C for 30 min and a 5-min incubation at 94°C, samples were
subjected to 35 rounds of amplification. Each cycle comprised a 1-min
denaturation step at 94°C, a 1-min annealing step at 55°C, and a
2-min extension step at 72°C. Nucleotide sequence analysis of the
amplified product was performed with the fmol DNA sequencing system
(Promega, Madison, Wis.) with the following primers: 14RD (5'
GCACGATATCTAATCCTGGTGTCTCA 3', complementary to positions
2540 to 2561), 3'RU (5' GCGGGATCCTGAAAATCCATACAATACTC 3',
positions 2278 to 2304), 15'RU (5' TAGATATCAGTACAATGTGCTTCCAC 3', positions 2555 to 2580), 58RU (5'
GCCAGAAAAAGACAGCTGGACTGT 3', positions 2867 to 2890), and
59RD (5' ATGATTCCTAATGCATATTGTGAGT 3', complementary to
positions 3622 to 3646). When sequences revealed a heterogeneity at a
given position, the relative proportion of each mutant was estimated by
densitometry of the specific bands in the sequencing gel, with a
PhosphorImager apparatus and the PCBAS program.
Expression and purification of recombinant HIV-1 RTs.
Recombinant HIV-1 RT mutants used in this study were previously
described (17, 18), except for those having Ile-230 instead of Met. In this case, the mutation was introduced with the Altered Sites in vitro mutagenesis system kit from Promega, following the
manufacturer's instructions. The mutagenic oligonucleotide used was 5'
GGAGTTCATAACCGATCCAAAGGAATGG 3', and the introduced mutation
was confirmed by DNA sequencing. Purification of mutant and wild-type
(WT) HIV-1 RTs was carried out after independent expression of their
subunits (p66 and p51), by following a previously described procedure
(17). The 51-kDa subunit was obtained with an extension of
14 amino acid residues at its N-terminal end, including six consecutive
histidines to facilitate its purification by metal chelate affinity
chromatography. All RTs were purified as p66-p51 heterodimers. Briefly,
RTs were prepared by mixing the cell pellets of p66 and p51 clones at a
10:1-to-15:1 ratio. The bacteria were lysed, sonicated, and
centrifuged, and supernatants were applied to a nickel-nitriloacetic
acid-agarose column (Invitrogen Corporation, Carlsbad, Calif.). The
column was washed, and histidine-tagged RT was eluted with an imidazole
gradient. RT-containing fractions were pooled; dialyzed against 50 mM
Tris-HCl (pH 7.0) containing 25 mM NaCl, 1 mM EDTA, 1 mM
dithiothreitol, and 10% glycerol (buffer A); and then passed through Q
Sepharose (Amersham Pharmacia, Uppsala, Sweden). The RT was recovered
in the nonbinding fraction and loaded onto Bio-Rex 70 (Bio-Rad
Laboratories, Hercules, Calif.). RT was eluted with an NaCl gradient,
and the RT-containing fractions were dialyzed against buffer A,
concentrated in Centriprep-30 and Centricon-30 (Amicon, Beverly, Mass.)
to less than 0.5 ml, and stored at
20°C. RT preparations were up to
90 to 95% pure, as judged by examination of Coomassie blue-stained gels.
Single nucleotide extension assays.
Oligonucleotides PG5 (5'
TGGTAGGGCTATACAT 3') and pT (5' GGATTTTAGACAGGAACGGT
3') were labeled at their 5' termini with
[
-32P]ATP with T4 polynucleotide kinase, as previously
described (18). The phosphorylated primers were then
annealed to templates. In the case of PG5, the template used was D2 (5'
GGGATTAAATAAAATAGTAAGAATGTATAGCCCTACCA 3'), a 38-mer
synthetic oligonucleotide representing the HIV-1 gag
sequence that extends from nucleotides 1137 (5' end) to 1174 (3' end)
according to the sequence numbering of Ratner et al. (27).
M13mp2 single-stranded DNA was the template used with oligonucleotide
pT. The templates and their corresponding primers were annealed in 150 mM NaCl-150 mM magnesium aspartate as described previously
(18). Nucleotide incorporation assays were performed in 20 µl of 50 mM HEPES (pH 7.0)-15 mM NaCl-15 mM magnesium
aspartate-130 mM KCH3COO-1 mM dithiothreitol-5%
polyethylene glycol 6000 (18). The template-primer
concentration was 30 nM for D2/PG5 and 20 nM for M13mp2 single-stranded
DNA/pT. The active enzyme concentration in these assays was around 6 nM. Reactions were initiated by incubating the enzyme with the
corresponding annealed template-primer in the absence of dNTP (10 min
at 37°C), followed by the addition of appropriate dNTPs at various
concentrations. The reaction mixtures were incubated for 30 s at
37°C, and then the reactions were stopped by adding 8 µl of 10 mM
EDTA in 90% formamide containing 3 mg of xylene cyanol FF per ml and 3 mg of bromophenol blue per ml. The extension products were resolved by
electrophoresis in 20% polyacrylamide-urea gels and quantitated with
a BAS 1500 scanner. Elongation measurements were fitted to the
Michaelis-Menten equation, and the kcat and
Km values were determined as previously
described (17).
 |
RESULTS |
In vitro replication of HIV-1 with mutations affecting Tyr-115 of
RT.
To examine the effect on virus replication of several
mutations affecting Tyr-115 of HIV-1 RT, we introduced the mutations Y115W, Y115L, Y115A, and Y115D into the proviral genome. COS-1 cells
were transfected with WT or mutated proviral DNA, and after addition of
MT-4 cells, coculture supernatants were monitored at various times for
RT activity and p24 antigen level. When WT DNA was used, RT activity
was detected around 12 days after transfection, reaching a maximum
level between days 14 and 18 (Fig. 1A),
and p24 was detected in the culture supernatants from day 9 (Fig. 1B).
In contrast, cultures transfected with mutants Y115L, Y115A, and Y115D
failed to produce any detectable RT activity even after 52 days of
culture and were found to be negative for the presence of p24 (values
indistinguishable from those of the mock-transfection assays in Fig.
1). Mutant Y115W displayed significant levels of RT activity from day
30 after transfection (Fig. 1A) and significant amounts of p24 in
culture supernatants from day 19 after transfection (Fig. 1B).
Supernatants of these cultures were able to infect MT-4 cells. The data
shown in Fig. 1 correspond to a single transfection experiment, but
similar results were obtained in three additional transfection
experiments. The WT virus and the virus recovered from transfections
with Y115W were the only ones that produced infectious progeny,
although the detection of RT activity in the supernatant was
significantly delayed in the case of Y115W, emerging more than 30 days
after transfection in the three other experiments (Table
1).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Replication kinetics of WT HIV-1 and Tyr-115 mutant
virus in MT-4 cells. COS-1 cells were transfected by electroporation
with 10 µg of each proviral DNA, as indicated in Materials and
Methods. Forty-eight hours after transfection, MT-4 cells were added.
Samples were withdrawn from cultures transfected with WT provirus
( ), mutant Y115W ( ), and mock (no DNA) ( ) at various days
after transfection and then assessed for RT activity (A) and for the
presence of p24 antigen (B).
|
|
Mutation M230I restores the replication capacity of the Y115W
mutant.
The complete RT coding region of viruses recovered from
transfections with the Y115W mutant was determined, after amplification of viral RNA from culture supernatants obtained at the peak of RT
activity. In all four transfection experiments, only one mutation was
observed in the RT coding region, which resulted in the substitution of
Ile for Met-230 (Table 1). This amino acid change was produced by a
G-to-A transition at the third base of codon 230. In two transfections,
a mixture of A and T was detected at this position (Table 1). In all
cases, Trp-115 was maintained. To monitor the kinetics of appearance of
the Ile-230 variant, we carried out RT-PCR and nucleotide sequence
analysis with transfection supernatants withdrawn on various days after
transfection (Fig. 2). A weak band of
amplification was obtained from supernatants collected on days 16 and
19 after transfection, indicating a very low level of viral
replication. By day 23, a significant increase in the amplified band
was observed. Nucleotide sequencing of the amplified products and a
quantitation of the relative proportions of Met and Ile at position 230 were also carried out. In the supernatants of day 23, Ile-230 appeared
instead of Met, and this was coincident with a sharp increase in the
amount of RT-PCR-amplified material. The appearance of substitution
M230I correlated with an increase in p24 antigen production (compare
Fig. 1B and 2). In the peak of RT activity (day 30 posttransfection of
transfection experiment 1), more than 95% of the viral population
contained Ile at position 230. These data reveal the rapid imposition
of a mutant HIV-1 with Ile at position 230. Mutations Y115W and M230I
were the only ones found in the RT-encoding region of viruses recovered
in any of the four experiments in which cells were transfected with
mutant Y115W. Thus, substitution M230I appears to restore the
replication capacity of mutant Y115W, as a compensatory mutation for
the presence of Trp at RT position 115.

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 2.
Kinetics of imposition of Ile over Met-230 in viruses
evolving after transfection with a clone harboring replacement Y115W.
RT-PCR was carried out with transfection supernatants obtained at
various days after transfection. Bands shown in lane M derive from
digestion of X174 DNA with HaeIII and correspond to
fragments of 1,353, 1,078, and 872 bp, top to bottom, respectively. The
relative amounts of Met and Ile at position 230 are shown below and
were estimated by densitometry of the specific bands in the sequencing
gels of the PCR products corresponding to days 21, 23, 26, and 28. Arrowheads indicate the position of the third base of codon 230 (G for
Met-230 and A for Ile-230).
|
|
Enzymatic characterization of RT mutants.
To study whether
M230I affected RT activity, steady-state kinetic parameters for the
incorporation of nucleotides at the 3' end of the primer were obtained
for the WT RT, the single mutants Y115W and M230I, and the double
mutant Y115W/M230I (Table 2). All of them
displayed roughly similar kcat values. However,
the Km values for the incorporation of dNTP were
75- to 130-fold higher for the single mutant Y115W than for the WT
enzyme, resulting in a reduced catalytic efficiency, which is the
likely cause of the replication defect observed in viruses harboring
this mutation. On the other hand, WT RT and single mutant M230I had
similar affinities for the incoming nucleotide. Interestingly, the
presence of M230I together with Y115W resulted in an enzyme with an
increased catalytic efficiency, which displayed a 9- to 65-fold-higher
affinity for dNTP, relative to the single mutant Y115W. This effect can
be attributed to the presence of both amino acid substitutions in the
66-kDa subunit of HIV-1 RT, as demonstrated by using chimeric heterodimers where substitutions were introduced in p66, p51, or both
subunits (Table 2).
The lower levels of RT activity obtained from transfection supernatants
with viruses having both mutations, Y115W and M230I (Fig. 1A), could be
explained by the lower affinity for dNTP of the double mutant than of
the WT enzyme, since those RT activity assays were carried out in the
presence of very low concentrations of dTTP. However, the high levels
of p24 antigen detected in transfection supernatants of WT and Y115W
(Fig. 1) suggested that viruses recovered from both transfection
experiments were viable and replicated normally. The growth curves
obtained upon infection of MT-4 cells with WT HIV-1 and the double
mutant Y115W/M230I show that the two viruses had similar replication
kinetics (Fig. 3). Interestingly, the
double-mutant virus was more sensitive to the concentration of dTTP in
the RT activity assay. In agreement with the enzymological data, the
differences in RT activity between the WT HIV-1 and the double-mutant
virus were minimized when the concentration of dTTP in the assay was
increased.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
Replication kinetics of WT HIV-1 and the double mutant
Y115W/M230I. MT-4 cells (106) were infected at a
multiplicity of infection of 0.01 PFU per cell. Infections were
monitored by measuring RT activity (A and B) and cell viability (C). RT
activity was determined either in the presence of 12.5 nM dTTP (A) or
in the presence of 10 µM dTTP (B). , WT HIV-1; , double mutant
Y115W/M230I; , mock.
|
|
 |
DISCUSSION |
Several lines of evidence support the role of Tyr-115 and Met-230
in RT function. We have found that viruses harboring the mutation
Y115L, Y115A, or Y115D showed no signs of virus replication (Table 1).
Similar results were previously reported for mutant Y115N
(16). In the present study, we have also shown that the Y115W variant replicates very poorly until the emergence of mutation M230I. Tyr-115 is part of a conserved motif in many polymerases (25). Tyr and Phe are the only amino acids found at this
position in retroviral RTs, and Phe is the only residue which can
replace Tyr-115 of HIV-1 RT without causing a detrimental effect in its DNA polymerase activity (17, 18). The Y115F appears in vitro after passage of the virus in the presence of abacavir and confers low-level resistance to this carbocyclic nucleoside inhibitor (32). In Moloney murine leukemia virus RT, an aromatic amino acid residue at this position is required for infectivity, since only
the WT Phe-155 or Tyr can support virus replication (7). Met-230 is part of a conserved motif found in many RNA-dependent DNA
polymerases, including RTs and telomerases (20, 25, 37). All
retroviral RTs have Met or Leu at this position. In the case of HIV-1,
the substitution of Leu for Met-230 has been detected in virus that was
passaged in cell culture, in the presence of the nonnucleoside RT
inhibitor delavirdine (23). Ile-230 has been found in one
nonproductive HIV-1 clone (5).
In this report, we demonstrate that the substitution of Ile for Met-230
restores the replication capacity of viruses having the Y115W mutation
in the RT to WT levels. To our knowledge, this is the most dramatic
compensatory effect described so far for HIV-1 clones with a defect in
polymerase function. Compensatory mutations play a role in the
acquisition of drug resistance, by increasing viral fitness. However,
they usually appear in viruses which already display a significant
replicative capacity. Examples for RT are the substitution of Ile for
Val-75 that improves the replication capacity of multidrug-resistant
viruses having the mutations Q151M and F77L (12) and the
substitution L74V, which, besides V75I, can stimulate viral growth in
quinoxaline-resistant viruses having substitution G190E (4,
14). In both cases, the compensatory mutation appears in the
FINGERS subdomain and could affect the positioning of the template in
the binding cleft of HIV-1 RT. Our results show that the substitution
Y115W impairs RT activity by decreasing the dNTP binding affinity of
the polymerase, but the acquisition of the M230I mutation compensates
for the dNTP binding defect. The crystallographic structure of HIV-1 RT reveals that Tyr-115 is located close to the polymerase active site,
while Met-230 is part of the primer grip which forms the
12-
13
hairpin, including residues 227 to 235. The ribose moiety of the
incoming dNTP projects into a small pocket lined by the side chains of
Asp-113, Tyr-115, Phe-116, and Gln-151 (11). Several amino
acid substitutions associated with resistance to nucleoside analogue
inhibitors lie within the dNTP binding site (e.g., K65R, L74V, M184V,
F116Y, and Q151M) (1, 6, 30). Met-230 interacts with the
3'-terminal phosphate of the primer, making extensive contacts with
nucleotides of the 3' primer terminus and with the side chain of
Tyr-183 (6, 11, 13). It has been suggested that binding of
nonnucleoside RT inhibitors could induce a conformational change
leading to repositioning of the primer grip (6), but none of
the amino acids surrounding Met-230 appears to be involved in major
drug resistance mutations. Met-230 influences the proper positioning of
the RT on the template-primer. Its replacement by Ala led to
alterations of both polymerase and RNase H activities (8,
24) and affected RNA primer selection, a step which is important
at the initiation of minus-strand DNA synthesis (26). Not
surprisingly, the mutation M230A caused severe defects in proviral DNA
synthesis and rendered virus noninfectious (38).
Crystallographic data have implicated the primer grip in orienting the
primer terminus for nucleophilic attack on an incoming dNTP. In
agreement with this proposal, it has been shown that substitution of
Ala for Met-230 produces a significant decrease in the dNTP binding
affinity of the enzyme (35), an effect which is also
observed with mutant HIV-1 RTs having nonconservative substitutions at
position 115 (17, 18). Therefore, it is likely that Y115W
leads to a less favorable positioning of the
-phosphate dNTP for
attack by the 3' OH of the primer terminus, and mutation M230I
restores, at least in part, the proper alignment required for catalysis.
Restoration of RT function by direct reversion of Trp-115 to Tyr was
probably limited by the two mutations needed to convert the triplet for
Trp (UGG) into a triplet for Tyr (UAU or UAC). The two required
mutations had to occur simultaneously in the same genomic RNA molecule
since G
A alone would lead to the termination codon UAG, and G
U
(or G
C) alone would produce an RT with Cys at position 115, an
enzyme with a very high Km for dNTP binding (18). Therefore, the genetic makeup of the virus (its
initial position in sequence space) may have prompted replacement
M230I, thereby revealing the implication of this residue in RT
catalysis. The results described in this paper illustrate the enormous
adaptative potential of HIV-1 and should guide future mutagenesis
experiments with the aim of gaining a better knowledge of the DNA
polymerization mechanism catalyzed by RTs, by combining a biochemical
with an evolutionary approach.
 |
ACKNOWLEDGMENTS |
We thank Gema Gómez Mariano for help with DNA sequencing.
This work was supported by Fondo de Investigación Sanitaria
grants 98/0054-01, -02, and -03 and by an institutional grant of
Fundación Ramón Areces to Centro de Biología
Molecular "Severo Ochoa."
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Centro de
Biología Molecular "Severo Ochoa," Consejo Superior de
Investigaciones Científicas-Universidad Autónoma de
Madrid, Cantoblanco, 28049 Madrid, Spain. Phone: 34-91-3978477. Fax: 34-91-3974799. E-mail: LMENENDEZ{at}CBM.UAM.ES.
 |
REFERENCES |
| 1.
|
Arts, E. J., and M. A. Wainberg.
1996.
Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription.
Adv. Virus Res.
46:97-163[Medline].
|
| 2.
|
Boom, R.,
C. J. A. Sol,
M. M. M. Salimans,
C. L. Jansen,
P. M. E. Wertheim-van Dillen, and J. van der Noordaa.
1990.
Rapid and simple method for purification of nucleic acids.
J. Clin. Microbiol.
28:495-503[Abstract/Free Full Text].
|
| 3.
|
Boyer, P. L.,
A. L. Ferris,
P. Clark,
J. Whitmer,
P. Frank,
C. Tantillo,
E. Arnold, and S. H. Hughes.
1994.
Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase.
J. Mol. Biol.
243:472-483[Medline].
|
| 4.
|
Boyer, P. L.,
H.-Q. Gao, and S. H. Hughes.
1998.
A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template-primer.
Antimicrob. Agents Chemother.
42:447-452[Abstract/Free Full Text].
|
| 5.
|
Carlini, F.,
M. Federic,
M. Equestre,
S. Ricci,
G. Ratti,
Q. Zibai,
P. Verani, and G. B. Rossi.
1992.
Sequence analysis of HIV-1 proviral DNA from a non producer chronically infected HUT-78 cellular clone.
J. Viral Dis.
1:40-55.
|
| 6.
|
Ding, J.,
K. Das,
Y. Hsiou,
S. G. Sarafianos,
A. D. Clark, Jr.,
A. Jacobo-Molina,
C. Tantillo,
S. H. Hughes, and E. Arnold.
1998.
Structural and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution.
J. Mol. Biol.
284:1095-1111[Medline].
|
| 7.
|
Gao, G., and S. P. Goff.
1998.
Replication defect of Moloney murine leukemia virus with a mutant reverse transcriptase that can incorporate ribonucleotides and deoxyribonucleotides.
J. Virol.
72:5905-5911[Abstract/Free Full Text].
|
| 8.
|
Ghosh, M.,
P. S. Jacques,
D. W. Rodgers,
M. Ottmann,
J.-L. Darlix, and S. F. J. Le Grice.
1996.
Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization.
Biochemistry
35:8553-8562[Medline].
|
| 9.
|
Harada, S.,
Y. Koyanagi, and N. Yamamoto.
1985.
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.
Science
229:563-566[Abstract/Free Full Text].
|
| 10.
|
Hottiger, M., and U. Hübscher.
1996.
Human immunodeficiency virus type 1 reverse transcriptase.
Biol. Chem. Hoppe-Seyler
377:97-120[Medline].
|
| 11.
|
Huang, H.,
R. Chopra,
G. L. Verdine, and S. C. Harrison.
1998.
Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.
Science
282:1669-1675[Abstract/Free Full Text].
|
| 12.
|
Iversen, A. K. N.,
R. W. Shafer,
K. Wehrly,
M. A. Winters,
J. I. Mullins,
B. Chesebro, and T. C. Merigan.
1996.
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
J. Virol.
70:1086-1090[Abstract].
|
| 13.
|
Jacobo-Molina, A.,
J. Ding,
R. G. Nanni,
A. D. Clark, Jr.,
X. Lu,
C. Tantillo,
R. L. Williams,
G. Kamer,
A. L. Ferris,
P. Clark,
A. Hizi,
S. H. Hughes, and E. Arnold.
1993.
Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA.
Proc. Natl. Acad. Sci. USA
90:6320-6324[Abstract/Free Full Text].
|
| 14.
|
Kleim, J.-P.,
M. Rösner,
I. Winkler,
A. Paessens,
R. Kirsch,
Y. Hsiou,
E. Arnold, and G. Riess.
1996.
Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74 Val or Ile and Val-75 Leu or Ile) HIV-1 mutants.
Proc. Natl. Acad. Sci. USA
93:34-38[Abstract/Free Full Text].
|
| 15.
|
Kohlstaedt, L. A.,
J. Wang,
J. M. Friedman,
P. A. Rice, and T. A. Steitz.
1992.
Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor.
Science
256:1783-1790[Abstract/Free Full Text].
|
| 16.
|
Larder, B. A.,
S. D. Kemp, and D. J. M. Purifoy.
1989.
Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.
Proc. Natl. Acad. Sci. USA
86:4803-4807[Abstract/Free Full Text].
|
| 17.
|
Martín-Hernández, A. M.,
E. Domingo, and L. Menéndez-Arias.
1996.
Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis.
EMBO J.
15:4434-4442[Medline].
|
| 18.
|
Martín-Hernández, A. M.,
M. Gutiérrez-Rivas,
E. Domingo, and L. Menéndez-Arias.
1997.
Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115.
Nucleic Acids Res.
25:1383-1389[Abstract/Free Full Text].
|
| 19.
|
Menéndez-Arias, L.
1998.
Studies on the effects of truncating -helix E' of p66 human immunodeficiency virus type 1 reverse transcriptase on template-primer binding and fidelity of DNA synthesis.
Biochemistry
37:16636-16644[Medline].
|
| 20.
|
Nakamura, T. M.,
G. B. Morin,
K. B. Chapman,
S. L. Weinrich,
W. H. Andrews,
J. Lingner,
C. B. Harley, and T. R. Cech.
1997.
Telomerase catalytic subunit homologs from fission yeast and human.
Science
277:955-959[Abstract/Free Full Text].
|
| 21.
|
Olivares, I.,
G. Shaw, and C. López-Galíndez.
1997.
Phenotypic switch in a Spanish HIV type 1 isolate on serial passage on MT-4 cells.
AIDS Res. Hum. Retroviruses
13:979-984[Medline].
|
| 22.
|
Olivares, I.,
C. Casado Herrero,
M. D. Iglesias-Ussel,
U. Dietrich, and C. López-Galíndez.
1998.
Complete sequence of an infectious molecular clone derived from a Spanish HIV type I isolate.
AIDS Res. Hum. Retroviruses
14:1649-1651[Medline].
|
| 23.
|
Olmsted, R. A.,
D. E. Slade,
L. A. Kopta,
S. M. Poppe,
T. J. Poel,
S. W. Newport,
K. B. Rank,
C. Biles,
R. A. Morge,
T. J. Dueweke,
Y. Yagi,
D. L. Romero,
R. C. Thomas,
S. K. Sharma, and W. G. Tarpley.
1996.
(Alkylamino)piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.
J. Virol.
70:3698-3705[Abstract].
|
| 24.
|
Palaniappan, C.,
M. Wisniewski,
P. S. Jacques,
S. F. J. Le Grice,
P. J. Fay, and R. A. Bambara.
1997.
Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function.
J. Biol. Chem.
272:11157-11164[Abstract/Free Full Text].
|
| 25.
|
Poch, O.,
I. Sauvaget,
M. Delarue, and N. Tordo.
1989.
Identification of four conserved motifs among the RNA-dependent polymerase encoding elements.
EMBO J.
8:3867-3874[Medline].
|
| 26.
|
Powell, M. D.,
M. Ghosh,
P. S. Jacques,
K. J. Howard,
S. F. J. Le Grice, and J. G. Levin.
1997.
Alanine-scanning mutations in the "primer grip" of p66 HIV-1 reverse transcriptase result in selective loss of RNA priming activity.
J. Biol. Chem.
272:13262-13269[Abstract/Free Full Text].
|
| 27.
|
Ratner, L.,
W. Haseltine,
R. Patarca,
K. J. Livak,
B. Starcich,
S. F. Josephs,
E. R. Doran,
J. A. Rafalski,
E. Whitehorn,
K. Baumeister,
L. Ivanoff,
S. R. Petteway, Jr.,
M. L. Pearson,
J. A. Lautenberger,
T. S. Papas,
J. Ghrayeb,
N. T. Chang,
R. C. Gallo, and F. Wong-Staal.
1985.
Complete nucleotide sequence of the AIDS virus, HTLV-III.
Nature
313:277-284[Medline].
|
| 28.
|
Rodgers, D. W.,
S. J. Gamblin,
B. A. Harris,
S. Ray,
J. S. Culp,
B. Hellmig,
D. J. Woolf,
C. Debouck, and S. C. Harrison.
1995.
The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
92:1222-1226[Abstract/Free Full Text].
|
| 29.
|
Sánchez-Palomino, S.,
J. M. Rojas,
M. A. Martínez,
E. M. Fenyö,
R. Nájera,
E. Domingo, and C. López-Galíndez.
1993.
Dilute passage promotes expression of genetic and phenotypic variants of human immunodeficiency virus type 1 in cell culture.
J. Virol.
67:2938-2943[Abstract/Free Full Text].
|
| 30.
|
Tantillo, C.,
J. Ding,
A. Jacobo-Molina,
R. G. Nanni,
P. L. Boyer,
S. H. Hughes,
R. Pauwels,
K. Andries,
P. A. J. Janssen, and E. Arnold.
1994.
Location of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
J. Mol. Biol.
243:369-387[Medline].
|
| 31.
|
Telesnitsky, A., and S. P. Goff.
1997.
Reverse transcriptase and the generation of retroviral DNA, p. 121-160.
In
J. W. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Plainview, N.Y.
|
| 32.
|
Tisdale, M.,
T. Alnadaf, and D. Cousens.
1997.
Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.
Antimicrob. Agents Chemother.
41:1094-1098[Abstract].
|
| 33.
|
Wakefield, J. K.,
S. A. Jablonski, and C. D. Morrow.
1992.
In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome.
J. Virol.
66:6806-6812[Abstract/Free Full Text].
|
| 34.
|
Willey, R. L.,
D. H. Smith,
L. A. Lasky,
T. S. Theodore,
P. L. Earl,
D. Moss,
D. J. Capon, and M. A. Martin.
1988.
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.
J. Virol.
62:139-147[Abstract/Free Full Text].
|
| 35.
|
Wöhrl, B. M.,
R. Krebs,
S. H. Thrall,
S. F. J. Le Grice,
A. J. Scheidig, and R. S. Goody.
1997.
Kinetic analysis of four HIV-1 reverse transcriptase enzymes mutated in the primer grip region of p66. Implications for DNA synthesis and dimerization.
J. Biol. Chem.
272:17581-17587[Abstract/Free Full Text].
|
| 36.
|
Wrobel, J. A.,
S.-F. Chao,
M. J. Conrad,
J. D. Merker,
R. Swanstrom,
G. J. Pielak, and C. A. Hutchison, III.
1998.
A genetic approach for identifying critical residues in the fingers and palm subdomains of HIV-1 reverse transcriptase.
Proc. Natl. Acad. Sci. USA
95:638-645[Abstract/Free Full Text].
|
| 37.
|
Xiong, Y., and T. H. Eickbush.
1990.
Origin and evolution of retroelements based upon their reverse transcriptase sequences.
EMBO J.
9:3353-3362[Medline].
|
| 38.
|
Yu, Q.,
M. Ottmann,
C. Pechoux,
S. Le Grice, and J.-L. Darlix.
1998.
Mutations in the primer grip of human immunodeficiency virus type 1 reverse transcriptase impair proviral DNA synthesis and virion maturation.
J. Virol.
72:7676-7680[Abstract/Free Full Text].
|
Journal of Virology, August 1999, p. 6293-6298, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mateo, R., Mateu, M. G.
(2007). Deterministic, Compensatory Mutational Events in the Capsid of Foot-and-Mouth Disease Virus in Response to the Introduction of Mutations Found in Viruses from Persistent Infections. J. Virol.
81: 1879-1887
[Abstract]
[Full Text]
-
Smith, R. A., Anderson, D. J., Preston, B. D.
(2006). Hypersusceptibility to Substrate Analogs Conferred by Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase. J. Virol.
80: 7169-7178
[Abstract]
[Full Text]
-
Cases-Gonzalez, C. E., Menendez-Arias, L.
(2004). Increased G->A Transition Frequencies Displayed by Primer Grip Mutants of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. J. Virol.
78: 1012-1019
[Abstract]
[Full Text]
-
Delaney, W. E. IV, Yang, H., Westland, C. E., Das, K., Arnold, E., Gibbs, C. S., Miller, M. D., Xiong, S.
(2003). The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro. J. Virol.
77: 11833-11841
[Abstract]
[Full Text]
-
Beck, J., Vogel, M., Nassal, M.
(2002). dNTP versus NTP discrimination by phenylalanine 451 in duck hepatitis B virus P protein indicates a common structure of the dNTP-binding pocket with other reverse transcriptases. Nucleic Acids Res
30: 1679-1687
[Abstract]
[Full Text]
-
Gutierrez-Rivas, M., Menendez-Arias, L.
(2001). A mutation in the primer grip region of HIV-1 reverse transcriptase that confers reduced fidelity of DNA synthesis. Nucleic Acids Res
29: 4963-4972
[Abstract]
[Full Text]
-
Ikuta, K., Suzuki, S., Horikoshi, H., Mukai, T., Luftig, R. B.
(2000). Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis. Microbiol. Mol. Biol. Rev.
64: 725-745
[Abstract]
[Full Text]
-
García-Lerma, J. G., Gerrish, P. J., Wright, A. C., Qari, S. H., Heneine, W.
(2000). Evidence of a Role for the Q151L Mutation and the Viral Background in Development of Multiple Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1. J. Virol.
74: 9339-9346
[Abstract]
[Full Text]
-
Cases-Gonzalez, C. E., Gutierrez-Rivas, M., Menendez-Arias, L.
(2000). Coupling Ribose Selection to Fidelity of DNA Synthesis. THE ROLE OF Tyr-115 OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE. J. Biol. Chem.
275: 19759-19767
[Abstract]
[Full Text]